Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416982 | 0.91 | MAPT (0.45) | EGFRAURKBSMN1; SMN2MAPTTP53 | |
| SCHEMBL6416313 | 0.86 | MAPT (0.47) | EGFRSMN1; SMN2MAPTTP53CCR2 | |
| SCHEMBL6419799 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTTP53CCR2CCR5 | |
| SCHEMBL6419677 | 0.81 | GAA (0.49) | SMN1; SMN2MAPTTP53CCR2CCR5 | |
| SCHEMBL15559868 | 0.79 | HTT (0.52) | EGFRAURKBSMN1; SMN2MAPTHTT | |
| SCHEMBL3054066 | 0.74 | MAPT (0.43) | EGFRAURKBSMN1; SMN2MAPTTP53 | |
| SCHEMBL6416881 | 0.74 | MAPT (0.51) | EGFRSMN1; SMN2MAPTTP53CCR2 | |
| SCHEMBL6416039 | 0.74 | MEN1 (0.44) | SMN1; SMN2MAPTTP53HTTMEN1 | |
| SCHEMBL3060981 | 0.73 | MAPT (0.44) | EGFRAURKBSMN1; SMN2MAPTTP53 | |
| Hydrochloric Acid SCHEMBL6413527 | 0.73 | MAPT (0.50) | EGFRSMN1; SMN2MAPTTP53CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | EGFR 1083/4885AURKB 1529/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.